ClinicalTrials.gg
CompletedNCT05519865Updated Apr 20, 2026

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

A Phase 2 interventional study of Tucidinostat and Tislelizumab in Non Small Cell Lung Cancer, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Enrollment
731st of 1,593
118 · median 100
Started
2022
with 169 others
Phase 2
650 of 1,880
273 open now
Registered
1,035th of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 731st largest by enrollment of the 1,593 interventional ones that give a count, is one of 170 that started in 2022, is one of 650 in phase 2, and was the 1,035th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Controlled, Multi-center Phase 2 Clinical study to Investigate the Efficacy and Safety of Tucidinostat (Chidamide) Combined with Tislelizumab as First-line Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, Male or female.
  2. or cytologically confirmed diagnosis of unresectable locally advanced or (stage IIIB-IV) NSCLC.
  3. Must have no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.
  4. Must have positive expression in tumor tissue.
  5. performance status of 0 or 1.
  6. Must Have ≥1 measurable target lesion as defined by v.1.1.
  7. Must have adequate organ function.
  8. ≥ 12 weeks.
  9. Signed form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. With EGFR or ALK gene mutation.
  2. Received prior targeted therapy.
  3. Prior use of HDAC inhibitor.
  4. Received prior therapies targeting , PD-L1, CTLA4, or any other immune checkpoint pathway.
  5. Received any anti-tumor therapy or agent and device within 28 days before the first dose of study treatment.
  6. Received radiotherapy within 2 weeks or thoracic radiation >30Gy within 6 months before the first dose of study treatment.
  7. Received systemic drugs within 28 days before the first dose of study treatment. Inhaled or topical and physiological dose of systemic glucocorticoid (≤10 mg daily prednisone equivalents) are permitted.
  8. Received systemic immunostimulatory drugs within 28 days before the first dose of study treatment.
  9. Received a within 28 days before the first dose of study treatment or planned to receive during the study period. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; and COVID-19 vaccine also are allowed.
  10. Received major surgery within 28 days before the first dose of study treatment.
  11. Has not recovered ( ≤ Grade 1 defined by V5.0) from AEs due to prior anti-cancer therapy.
  12. Has symptomatic and untreated central nervous system (CNS) .
  13. Has hydrothorax and ascites with obvious symptoms or requiring repeated drainage within 1 month before the first dose of study treatment.
  14. Uncontrollable or major cardiovascular and cerebrovascular disease.
  15. History of hemoptysis within 2 weeks or active bleeding within 2 months before the first dose of study treatment; or subject who is taking anticoagulants, or subject with clear high-risk bleeding tendency during the screening period.
  16. History of serious thromboembolism within 6 months before the first dose of study treatment.
  17. Suspected interstitial lung disease (ILD) or pulmonary fibrosis or pulmonary inflammation requiring treatment; or history of lung disease treated with oral or intravenous steroids within 6 months before the first dose of study treatment.
  18. Obvious gastrointestinal abnormalities during the screening period, which may affect the intake, transport or absorption of drugs.
  19. Urinary protein ≥ 2+ and quantitative urinary protein ≥ 1g/24 h during the screening period.
  20. Active infection requiring intravenous therapy; or severe infection within 28 days before the first dose of study treatment.
  21. Known active pulmonary tuberculosis, or subject who is receiving antituberculous treatment or having received antituberculous treatment within 1 year before the first dose of study treatment.
  22. Active or .
  23. positive or history of AIDS or other serious infectious diseases.
  24. History of malignant tumor.
  25. Active diseases during the screening period, and have received systemic treatment within 2 years before the first dose of study treatment.
  26. History of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  27. to any of the study drug ingredients.
  28. History of to monoclonal antibody, Chidamide, study drugs, or any of its .
  29. History of alcohol or drug abuse.
  30. Unwilling or unable to comply with procedures required in this protocol.
  31. Pregnant or breast-feeding women. Male/Female is unwilling or unable to use a highly effective method of .

33. Any condition not suitable for participating in the trial in the opinion of the Investigator.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Tucidinostat Combined with Tislelizumab

    Subjects receive Tucidinostat 30mg orally biw and Tislelizumab 200 mg intravenously (IV) Q3W.

    Drug: Tucidinostat · Drug: Tislelizumab

  • Active comparator
    Tislelizumab

    Subjects receive Tislelizumab 200 mg intravenously (IV) Q3W.

    Drug: Tislelizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) per RECIST v1.1

    PFS assessed by investigator per RECIST v1.1, measured from the date of randomization until progression or death, whichever is first met.

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall response rate (ORR)

    Proportion of participants who have a partial response (PR) or complete response (CR) to therapy according to RECIST 1.1 or iRECIST.

    Time frame: Up to 2 years

  2. Progression Free Survival (PFS) per iRECIST

    PFS assessed by investigator per iRECIST, measured from the date of randomization until progression or death, whichever is first met.

    Time frame: Up to 2 years

  3. Overall Survival (OS)

    From the first dose of treatment until the date of death from any cause.

    Time frame: Up to 2 years

  4. Disease control rate (DCR)

    Proportion of participants in partial, complete or stable disease according to RECIST 1.1 or iRECIST.

    Time frame: Up to 2 years

  5. Duration of response (DOR)

    From the first date of response until the date of first documented progression according to RECIST 1.1 or iRECIST.

    Time frame: Up to 2 years

  6. Progression-free survival of 6 months

    Proportion of subjects who did not have disease progression(according to RECIST1.1 or iRECIST) or death at 6 months after randomization.

    Time frame: 6 months after randomization

  7. time to progression (TTP)

    TTP is measured from date of randomization until progression(according to RECIST1.1 or iRECIST) not including death.

    Time frame: Up to 2 years

  8. time to response (TTR)

    TTR is measured from date of randomization until response

    Time frame: Up to 2 years

  9. Safety and Tolerability

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: Up to 2 years

07

Study locations

1 site
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Nov 2024, 24 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 24 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 29, 2022
StartActual
Oct 26, 2022
Primary completionActual
Nov 18, 2024
CompletionActual
Nov 18, 2024
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05519865
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
Oct 26, 2022
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update
Apr 20, 2026

Study contacts

Caicun Zhou
principal investigator · caicunzhoudr@163.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucidinostat

Start the discussion